Positive Updated Results from RAMP 205 of Avutometinib, Defactinib and SOC chemo in 1L Metastatic Pancreatic Cancer Announced June 23, 2026
First Patient Dosed in TARGET-D 201 Ph 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Metastatic Pancreatic Cancer June 23, 2026
Multiple Complete Responses Reported After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer June 23, 2026
FAILED TRIAL: Ph 2 AMPLIFY-7P trial did not meet the pre-specified primary endpoint of DFS in the ITT adjuvant pancreatic cancer population June 17, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer June 10, 2026
Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer June 10, 2026
FDA Orphan Drug Designation Granted to Oxaliplatin for the Treatment of Pancreatic Cancer June 2, 2026
FDA cleared IND for Ph 1/2 study of oral elraglusib in metastatic melanoma, NSCLC, colorectal, and pancreatic cancers May 12, 2026
Study initiated to evaluate Pidnarulex (CX-5461) + tislelizumab in pancreatic cancer, colorectal cancer, and melanoma May 12, 2026
FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer May 6, 2026
Positive Ph 2a Data with Namodenoson in Pancreatic Cancer Reported; 35% of Patients Remain on Therapy, Including One Beyond 16 Months May 6, 2026
Ph 2/3 Clinical Trial Application submitted to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer May 6, 2026
First Pancreatic Cancer Patient in Europe treated with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial April 28, 2026
FDA Fast Track Designation for BBO-11818 for Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma April 28, 2026
Daraxonrasib Demonstrates Unprecedented OS Benefit in Ph 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer April 21, 2026
Nature Medicine Publishes Results Showing Doubling of the Rate of Survival with Elraglusib + Chemo in 1L Metastatic Pancreatic Ductal Adenocarcinoma April 21, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Positive Topline Results from Ph 2 PANOVA-4 Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer Announced March 31, 2026
Israeli Ministry of Health approves initiation of Ph 2/3 trial of SIL204 for the treatment of locally advanced pancreatic cancer March 31, 2026
